Free tool
FAERS Monitor: Ubrelvy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211765 or its brand name (Ubrelvy, Ubrogepant). Reports on generic versions are filed under their own applications.
Reports
6,366
Serious
2,277
36% of reports
Hospitalization
693
Death reported
107
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,069
- migraine921
- headache575
- nausea553
- fatigue389
- off label use300
- dizziness282
- pain280
- product dose omission issue240
- vomiting226
- pruritus188
- diarrhoea178
- injection site pain174
- somnolence166
- feeling abnormal159
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 9 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 17 |
| 2020 | 449 |
| 2021 | 643 |
| 2022 | 1,125 |
| 2023 | 947 |
| 2024 | 1,053 |
| 2025 | 1,096 |
| 2026 | 1,021 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,793 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| migraineSignal | 921 | 32.2 | 30.3 | 27,648 |
| headacheSignal | 575 | 3.0 | 2.8 | 804 |
| somnolenceSignal | 166 | 2.7 | 2.3 | 181 |
| product dose omission issueSignal | 240 | 2.7 | 2.4 | 258 |
| drug ineffectiveSignal | 1,069 | 2.7 | 2.5 | 1,200 |
| nauseaSignal | 553 | 2.3 | 2.1 | 425 |
| feeling abnormalSignal | 159 | 2.2 | 1.9 | 103 |
| injection site pain | 174 | 1.9 | 1.6 | 71 |
| dizziness | 282 | 1.9 | 1.7 | 116 |
| fatigue | 389 | 1.7 | 1.5 | 103 |
| pruritus | 188 | 1.6 | 1.4 | 44 |
| vomiting | 226 | 1.6 | 1.4 | 50 |
| pain | 280 | 1.5 | 1.3 | 49 |
| off label use | 300 | 1.1 | 1.0 | 5 |
| diarrhoea | 178 | 0.9 | 0.8 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.